Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-β-phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques

Journal of Mass Spectrometry

Volumn 41, Issue 11, 2006, Pages 1509-1519

  Theobald, Denis S ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

2,5 dimethoxy 4 methyl phenethylamine; 2C D; Designer drug; GC MS; Metabolism

Indexed keywords

DRUG PRODUCTS; GAS CHROMATOGRAPHY; HYDROXYLATION; IMPURITIES; MASS SPECTROMETRY; METABOLISM; TOXICITY;

DESIGNER DRUGS; SYSTEMATIC TOXICOLOGICAL ANALYSIS (STA); TOXICOLOGICAL DETECTION; URINE;

AMINES;

2,5 DIMETHOXY 4 METHYL BETA PHENETHYLAMINE; ALCOHOL; DESIGNER DRUG; DRUG METABOLITE; PHENETHYLAMINE DERIVATIVE;

ACETYLATION; ANIMAL EXPERIMENT; ARTICLE; CONJUGATION; CONTROLLED STUDY; DEAMINATION; DEMETHYLATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; GAS CHROMATOGRAPHY; HYDROXYLATION; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; REDUCTION; URINE;

ANIMALS; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MOLECULAR STRUCTURE; PHENETHYLAMINES; RATS; RATS, WISTAR;

EID: 33845202633     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1128     Document Type: Article

References (51)

1. de Boer D, Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci. 2004; 26: 110.
2. Shulgin A. Pihkal, A Chemical Love Story, 1st edn. Transform Press: Berkley, 1991.
3. Allred RA. Spectral characterization of 2,4-dimethoxy-3- methylphenethylamine, and comparison to 2,5-dimethoxy-4-methylphenetylamine (2C-D). Microgram J. 2005; 3: 16.
4. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-Dimethoxy-4-Ethylphenethylamine (2C-E) Encountered In FT. Pierce, Florida and Royal Oak, Michigan. Microgram 2004; 37: 193.
5. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-dimethoxy-4-ethylphenethylamine (2C-E) capsules in bettendorf, Iowa. Microgram 2005; 38: 59.
6. Johnson MP, Mathis CA, Shulgin AT, Hoffman AJ, Nichols DE. [125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav. 1990; 35: 211.
7. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 1992; 35: 734.
8. Glennon RA, Titeler M, Lyon RA. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol. Biochem. Behav. 1988; 30: 597.
9. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 1996; 39: 2953.
10. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol. 2002; 136: 510.
11. Villalobos CA, Bull P, Saez P, Cassels BK, Huidobro-Toro JP. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 2004; 141: 1167.
12. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dirnethoxy-4-(n)- propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl.) 2005; 181: 496.
13. Saez P, Borges Y, Gonzalez E, Cassels BK. Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen. Pharmacol. 1994; 25: 211.
14. Clare BW. The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J. Med. Chem. 1998; 41: 3845.
15. Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E, Veuthey JL, Kamalaprija P. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the swiss black market. J. Anal. Toxicol. 1998; 22: 345.
16. Tsai CC, Liu JT, Shu YR, Chan PH, Lin CH. Optimization of the separation and on-line sample concentration of phenethylamine designer drugs with capillary electrophoresis-fluorescence detection. J. Chromatogr. A 2006; 1101: 319.
17. Kikura-Hanajiri R, Hayashi M, Saisho K, Goda Y. Simultaneous determination of nineteen hallucinogenic tryptamines/beta-calbolines and phenethylamines using gas chromatography-mass spectrometry and liquid chromatography-electrospray ionisation-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 825: 29.
18. Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J. Anal. Toxicol. 2004; 28: 407.
19. Cole MD, Lea C, Oxley N. 4-Bromo-2,5-dimethoxyphenethyl amine (2C-B): a review of the public domain literature. Sci. Justice 2002; 42: 223.
20. de Boer D, Gijzels MJ, Bosman IJ, Maes RA. More data about the new psychoactive drug 2C-B [letter; comment], J. Anal. Toxicol. 1999; 23: 227.
21. Bosman IJ, de Boer D, Siderius EB. Lesseps JALdR, Maes RAA. Mass spectrometric identification of some sulphur containing phenalkylamine designer drugs. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, Spiehler V (ed.). TIAFT98: Albuquerque, 1999.
22. DeRuiter J, Clark CR, Noggle FT. LC and GC-MS analysis of 4-bromo-2,5-dimethoxyphenethylamine (Nexus) and 2-propanamine and 2-butanamine analogs. J. Chromatogr. Sci. 1995; 33: 583.
23. DeRuiter J, Clark CR, Noggle FT. Gas chromatographic-mass spectrometric and high-performance liquid chromatographic analyses of the bromination products of the regioisomeric dimethoxyphenethylamines: differentiation of Nexus from five positional isomers. J. Chromatogr. Sci. 1998; 36: 23.
24. Ragan FA Jr, Hite SA, Samuels MS, Garey RE. 4-Bromo-2,5- dimethoxyphenethylamine: identification of a new street drug. J. Anal. Toxicol. 1985; 9: 91.
25. Laks S, Pelander A, Vuori E, Ali-Tolppa E, Sippola E, Ojanpera I. Analysis of street drugs in seized material without primary reference standards. Anal. Chem. 2004; 76: 7375.
26. Boatto G, Nieddu M, Carta A, Pau A, Palomba M, Asproni B, Cerri R. Determination of amphetamine-derived designer drugs in human urine by SPE extraction and capillary electrophoresis with mass spectrometry detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 814: 93.
27. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2005; 40: 105.
28. Theobald DS, Staack RF, Puetz M, Maurer HH. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2005; 40: 1157.
29. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-〈beta〉- phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006; 842: 76.
30. Habrdova V, Peters FT, Theobald DS, Maurer HH. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 2005; 40: 785.
31. Theobald DS, Putz M, Schneider E, Maurer HH. New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J. Mass Spectrom. 2006; 41: 872.
32. de Boer D, Lesseps JALdR, Gijzels M, Pilon N, Bosman IJ, Maes RAA. Studies on the metabolism of 2C-B. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, Spiehler V (ed.). TIAFT98: Albuquerque, 1999.
33. de Boer D, dos Reys LA, Pylon N, Gijzels M, Bosman IJ, Maes RAA. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5- dimethoxyphenethylamine) and its metabolites in humans. Br. J. Pharmacol. 1999; 127: 41P.
34. Kanamori T, Inoue H, Iwata Y, Ohmae Y, Kishi T. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol. 2002; 26: 61.
35. Lin LC, Liu JT, Chou SH, Lin CH. Identification of 2,5-dimethoxy-4- ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003; 798: 241.
36. Kanamori T, Tsujikawa K, Ohmae Y, Iwata Y, Inoue H, Inouye Y, Kishi T. Excretory profile of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rat. J. Health Sci. 2003; 49: 166.
37. Carmo H, Boer D, Remiao F, Carvalho F, Reys LA, Bastos ML. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004; 811: 143.
38. Carmo H, Hengstler JG, de Boer D, Ringel M, Carvalho F, Fernandes E, Remiao F, dos Reys LA, Oesch F, De Lourdes BM. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol. 2004; 369: 198.
39. Kanamori T, Tsujikawa K, Ohmae Y, Iwata YT, Inoue H, Kishi T, Nakahama T, Inouye Y. A study of the metabolism of methamphetamine and 4-bromo-2,5- dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic Sci. Int. 2005; 148: 131.
40. Maurer HH. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control [review]. Clin. Chem. Lab. Med. 2004; 42: 1310.
41. Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 824: 123.
42. McLafferty FW, Turecek F. Interpretation of Mass Spectra, 4th edn. University Science Books: Mill Valley, 1993.
43. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. Wiley: New York, 1999.
44. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites, 4th edn. Agilent Technologies: Palo Alto, (in press).
45. Kovats E. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958; 41: 1915.
46. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special issue of the TIAFT Bulletin). 3rd edn. VCH Publishers: Weinheim, New York, Basle, 1992.
47. Beyer J, Ehlers D, Maurer HH. Abuse of Nutmeg (Myristica fragrans Houtt.): studies on the metabolism and the toxicological detection of its Ingredients Elemicin, Myristicin and Safrole in Rat and Human Urine using gas Chromatography/mass spectrometry. Ther. Drug Monit. 2006; 28: 568.
48. Ewald AH, Fritschi G, Bork WR, Maurer HH. Designer drugs 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2006; 41: 487.
49. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int. 2005; 153: 85.
50. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol Biomed. Life Sci. 2002; 773: 35.
51. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.